Tanezumab (INN, codenamed RN624) is a monoclonal antibody against nerve growth factor. It was developed by Pfizer as a treatment for pain.
In 2009 there was a Phase III trial for knee pain due to osteoarthritis (OA). Another Phase III trial for hip pain in OA  was halted in June 2010 when some patients needed hip replacement.
Tanezumab is undergoing Phase II clinical trials for the treatment of various pain entities, including chronic low back pain, bone cancer pain, and interstitial cystitis.
In March 2012, the Anti-NGF Testing - FDA Committee voted in favor of a continuation of the development of nerve-blocking medications, as long as certain safety precautions were observed. 
A Phase III trial published in 2013 found tanezumab was superior to placebo for painful hip osteoarthritis.